Research programme: M4 muscarinic acetylcholine receptor modulators - AstraZeneca/Vanderbilt University

Drug Profile

Research programme: M4 muscarinic acetylcholine receptor modulators - AstraZeneca/Vanderbilt University

Alternative Names: M4 positive allosteric modulators - AstraZeneca/Vanderbilt University; PAMs - AstraZeneca/Vanderbilt University

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Vanderbilt University
  • Developer AstraZeneca; Vanderbilt University
  • Class
  • Mechanism of Action Muscarinic M4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Psychiatric disorders; Psychotic disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Psychotic-disorders in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for research development in Psychiatric-disorders in United Kingdom
  • 14 Jan 2013 Early research in Psychotic disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top